<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01818232</url>
  </required_header>
  <id_info>
    <org_study_id>LX4211.1-108-NRM</org_study_id>
    <secondary_id>LX4211.108</secondary_id>
    <nct_id>NCT01818232</nct_id>
  </id_info>
  <brief_title>Study to Determine the Absorption, Metabolism, and Excretion of [14C]LX4211 in Healthy Male Subjects</brief_title>
  <acronym>AME</acronym>
  <official_title>A Phase 1, Open-label, Nonrandomized, Single Dose Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-LX4211, Following Oral Administration, in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lexicon Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lexicon Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      This phase 1 study is to evaluate the pharmacokinetics (PK), metabolism, routes and extent of
      elimination of a single oral dose of 400 mg [14C]LX4211 to healthy male subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under Curve (AUC)</measure>
    <time_frame>Day 1: predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects experiencing an adverse event</measure>
    <time_frame>Day 1 through discharge</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary recovery of radioactivity</measure>
    <time_frame>predose through 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal recovery of radioactivity</measure>
    <time_frame>predose through 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole blood and plasma concentration of total radioactivity</measure>
    <time_frame>predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>[14C]-LX4211</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg LX4211 administered orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-LX4211</intervention_name>
    <arm_group_label>[14C]-LX4211</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults ≥18 to ≤55 years of age

          -  Vital signs at Screening in the following ranges: systolic blood pressure, 90-140 mm
             Hg; diastolic blood pressure, 50-90 mm Hg; heart rate, 50-100 bpm

          -  Body mass index (BMI) ≥18 and ≤35 kg/sq m

          -  Historically able to produce a minimum of 1 bowel movement per day

          -  Willing and able to provide written informed consent

        Exclusion Criteria:

          -  Female

          -  Receipt of any investigational drug within 30 days prior to Dosing, or investigational
             protein or antibody-based therapeutic agents within 3 months prior to Screening

          -  Prior exposure to LX4211

          -  Use any tobacco product within 2 months prior to Screening and while participating in
             the study (Day -1 through Discharge)

          -  History of bariatric surgery or any other GI surgery that may induce malabsorption

          -  History of any major surgery within 6 months prior to Screening

          -  History of renal or hepatic disease, or significantly abnormal kidney or liver
             function tests at Screening

          -  History of any clinically relevant psychiatric, renal, hepatic, pancreatic,
             cardiovascular, neurological, hematological, or GI abnormality

          -  History of any active infection within 14 days prior to Dosing

          -  History of alcohol or substance abuse within 2 years prior to Dosing

          -  History of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C

          -  Donation or loss of &gt;400 mL of blood or blood product within 3 months of Dosing

          -  Positive urine glucose at Screening

          -  Positive urine screen for drugs of abuse at Screening or Day -1

          -  Positive breath test for alcohol at Screening or Day -1

          -  Participation in &gt;1 other radiolabeled investigational study drug trial within 12
             months prior to Day -1

          -  Exposure to significant radiation within 12 months prior to Day -1
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ikenna Ogbaa, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Lexicon Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lexicon Investigational Site</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2013</study_first_submitted>
  <study_first_submitted_qc>March 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2013</study_first_posted>
  <last_update_submitted>June 17, 2013</last_update_submitted>
  <last_update_submitted_qc>June 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

